Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
430.14
+4.13 (0.97%)
At close: Apr 28, 2026, 4:00 PM EDT
428.13
-2.01 (-0.47%)
After-hours: Apr 28, 2026, 7:57 PM EDT
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 26 analysts with 12-month price forecasts for Vertex Pharmaceuticals stock have an average target of 539.69, with a low estimate of 414 and a high estimate of 641. The average target predicts an increase of 25.47% from the current stock price of 430.14.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock from 29 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 8 | 8 | 10 | 10 |
| Buy | 8 | 9 | 12 | 12 | 12 | 12 |
| Hold | 10 | 8 | 7 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 26 | 24 | 27 | 27 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $596 → $612 | Buy | Maintains | $596 → $612 | +42.28% | Apr 10, 2026 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $575 | Hold → Strong Buy | Upgrades | $575 | +33.68% | Mar 18, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $490 → $525 | Strong Buy | Maintains | $490 → $525 | +22.05% | Mar 11, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $570 → $596 | Buy | Maintains | $570 → $596 | +38.56% | Mar 10, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $571 → $598 | Strong Buy | Maintains | $571 → $598 | +39.02% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
13.30B
from 12.00B
Increased by 10.79%
Revenue Next Year
14.69B
from 13.30B
Increased by 10.47%
EPS This Year
19.48
from 15.32
Increased by 27.13%
EPS Next Year
22.31
from 19.48
Increased by 14.55%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 13.9B | 17.2B | ||||||
| Avg | 13.3B | 14.7B | ||||||
| Low | 12.1B | 13.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 16.1% | 29.5% | ||||||
| Avg | 10.8% | 10.5% | ||||||
| Low | 0.5% | -0.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 22.16 | 28.14 | ||||||
| Avg | 19.48 | 22.31 | ||||||
| Low | 17.01 | 16.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 44.6% | 44.5% | ||||||
| Avg | 27.1% | 14.6% | ||||||
| Low | 11.0% | -17.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.